Fezolinetant Benefits Women Not Suited for Hormone Therapy
PHILADELPHIA — Fezolinetant (Veozah) improved menopause-related vasomotor symptoms in women unsuited or unwilling to take hormone therapy, according to a pooled analysis of two phase III studies. The analysis of the SKYLIGHT-1 and -2 trials showed significant improvements with two different dosages of the newly approved drug versus placebo in both the frequency and severity […]
FDA OKs Hormone-Free Pill for Hot Flashes
The FDA approved the first-in-class drug fezolinetant (Veozah) for the treatment of moderate to severe hot flashes caused by menopause, the agency announced Friday. The oral neurokinin 3 (NK3) receptor antagonist is a non-hormonal treatment that works to block the activities of the NK3 receptor, which plays a role in the brain’s regulation of body […]